Quote & Headlines
5d 1m 3m 1y 5y 10y
To learn more about Seeking Alpha PRO, click here.
There are no Transcripts on GNMSF.
There are no News articles on GNMSF.
GNMSF vs. ETF Alternatives
Thursday, Aug 302012, 8:16 AMJ&J (JNJ) unit Janssen Biotech buys the global licensing rights to cancer agent daratumumab from Danish biotech Genmab in a deal that could eventually be worth over $1.1B. Janssen is paying $55M upfront and will make further payments following the achievement of development, regulatory and sales milestones. J&J is also investing $80M in Genmab in return for a 10.7% stake. (PR) |Thursday, Aug 302012, 8:16 AM| Comment!